National and Kapodistrian University of Athens
Σαρκώματα γυναικείου γεννητικού συστήματος
Abstract
dc:descriptionObjective: The aim of this assay is the study of the patients presenting with sarcoma of the female genital tract in α greek population and the drawing of conclusions regarding their epidemiologic profile, the prognostic factors that influence their outcome and the treatment approach . Patients and methods: All patients presenting with female genital tract sarcoma in the Athens University Clinic of Obstetrics and Gynecology (Alexandra Hospital) since1995 were recorded and their files was reviewed. Data were drawn from the file of the patients, the operation report, the pathology report and the archives of the oncology department. Patients were studied in three groups. The first group included those suffering from extrauterine carcinosarcoma, the second one those presenting with early stage (I or II) uterine sarcoma and the third one those diagnosed with advanced uterine sarcoma (stage III or IV). The epidemiologic profile of the patients was recorded, as well as their clinical characteristics and the treatment approach. In the group of patients presenting with extrauterine carcinosarcoma, immunochemistry was applied to the biopsy specimens. All patients were followed up regularly, according to the NCCN guidelines. Results: A) patients with extrauterine carcinosarcoma: Nine patients were diagnosed with extrauterine carcinosarcoma. There were four homologous and five heterologous carcinosarcomas. Five patients had early stage (FIGO I or II) disease. Seven of the patients were optimally debulked. All patients were treated with anthracycline-based chemotherapy following surgery. With regard to immunohistochemistry, all specimens were negative for CD34, c-erbB-2, estrogen and progesterone receptor expression. Five tumors overexpressed p53 and four specimens stained for Ki67. Four tumor specimens stained for VEGF and two for pan-T. Median time to progression was 13,5 months. The median overall survival was 32.9 months with no statistical difference between early and advanced stages. p53 overexpression demonstrated a trend for better overall survival, while none of the other immunohistochemical markers influenced survival. B) patients with early-stage uterine sarcoma: thirty one patients with early-stage uterine sarcoma were referred to our center for systemic chemotherapy. These patients were deemed high risk for relapse based on at least one of the following findings: tumor size >= 5cm, stage >=IB, grade 3 or mitotic count >= 20 / HPF. All patients were treated with anthracycline-based regimens. Seventeen (54.8%) patients received namely ifosfamide, etoposide and epirubicin, 6 (19.4%) patients were treated with doxorubicin and carboplatin, doxorubicin and ifosfamide was administered to 3 (9.6%) patients, while 5 (16.1%) patients received various anthracycline-based regimens. With a median follow-up of 82 months disease recurred in 12 (38.7%) patients. Five-year survival probability is estimated at 54%. Both median overall survival and time to progression for all patients have not been reached yet. Age and stage (I vs II) did not affect overall survival. advanced stage uterine sarcoma are characterized of an overall poor survival.
Degree
thesis:*- Grantor dc:publisher
- National and Kapodistrian University of Athens
- Year dc:date
- 2007
Author and committee
dc:creator, dc:contributor.*- Authors dc:creator
-
- Zorzou, Markella-Pagonitsa
- Ζώρζου, Μαρκέλα-Παγωνίτσα
Subjects
dc:subject × 20- Σάρκωμα
- Καρκινοσάρκωμα
- Λειομυοσάρκωμα
- Ενδομητρικό στρωματικό σάρκωμα
- Ανοσοϊστοχημεία
- Προγνωστικοί παράγοντες
- Ανθρακυκλίνη
- Ιφωσφαμίδη
- Ulterine sarcomas
- Carcinosarcoma
- Leiomyosarcoma
- Stromal sarcoma
- Immunochemistry
- Prognostic factors
- Anthracyclines
- Ifosfamide
- Ιατρική και Επιστήμες Υγείας
- Κλινική Ιατρική
- Medical and Health Sciences
- Clinical Medicine
Rights
- Language dc:language
- gre
Identifiers
dc:identifier.*- Identifier
- 10.12681/eadd/18378